QLT091001 regulatory update

FDA granted Orphan Drug designation for QLT's QLT091001 to treat Leber's congenital amaurosis (LCA) and retinitis pigmentosa (RP). The synthetic retinoid replacement therapy for 11-cis-retinal is in P...